Loading...

INMB INMUNE BIO INC Product Launches 8-K Filing

NMN

NMB

INMUNE BIO INC

(INMB)

2024 8-K

Show Summary

Summary

Equity Offerings

Regulatory Compliance

Investor Meetings

Rights Offerings

Investor Meetings

Financial Statements

Changes in management or co...

Investor Meetings

Patent Approval

Partnership Announcement

Conference Presentation

Conference Announcement

Financial Results

Conference Call

Investor Presentation

License Agreement

Investor Presentations

Clinical Trial Update

Rights Agreement Extension

Investor Presentation

Financial Results

Webinar Announcement

Research Publication

Conference Call

Investor Conference

Clinical Trial Update

Alzheimer's Trial Results

Conference Announcement

Sales Agreement

Financial Results and Busin...

Conference Call Announcement

Annual Meeting Results

Resignation of Director

Clinical Trial Update

Appointment of CEO Option

Bylaws Amendment

Stock Options Issued

Financial Results and Busin...

Data Announcement

Financial Results and Busin...

Conference Call Announcement

FDA Clinical Hold Lifted

Announcement of Phase I/II ...

FDA Clinical Hold

Amendment to Rights Agreement

Data Presentation at Symposium

Authorization for Phase II ...

Clinical Trial Application ...

Financial Results and Busin...

Patent Approval and Confere...

Conferences Announcement

Sales Agreement with BTIG, LLC

Earnings Report

Conference Presentation

Termination of CTI Plan

Annual Meeting Approval of ...

FDA Clearance for INKmune C...

Financial Results and Busin...

Conference Call Announcement

License Agreement Amendments

Data Presentation at Confer...

FDA Application for INKmune

Financial Results and Busin...

Conference Call Announcement

Options Issuance

External Links:

INmune Bio Inc. announced the completion of patient randomization for its Phase 2 trial targeting Early Alzheimer's Disease with elevated neuroinflammation biomarkers.

AI Assistant

INMUNE BIO INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.